Since the second version of the Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic …

Certolizumab pegol (Cimzia®) is currently the only PEGylated anti-TNFα biologic approved
for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, …

Background: Tumour necrosis factor α (TNFα) is a proinflammatory cytokine involved in the
pathogenesis of rheumatoid arthritis (RA). Treatment with TNFα inhibitors reduces disease …

Background An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized
controlled trials (RCTs) was endorsed at the Outcome Measures in Rheumatology (OMERACT) …

Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA)
clinical trials that represent both patients' and physicians' priorities. Methods We …

Objective To determine the relative contributions of genetic, clinical, serologic,
sociodemographic, and behavioral/psychological variables to early pulmonary involvement in the …

Objective To determine the factors associated with disease activity in patients with recent‐onset
(≤5 years) systemic lupus erythematosus (SLE) who were of Hispanic, African‐American…

Objective. To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad
population of patients with active RA. Methods. In this 12-week, double-blind period of the phase …

Objective. To include the patient perspective in accordance with the Outcome Measures in
Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set …

Background Guidelines suggest treatment in rheumatoid arthritis (RA) to target remission, in
close consultation with the patient. Our recent qualitative study of the patients' perspective …